2012 年多发性硬化症：多发性硬化症的新治疗选择和药物靶点。
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.
机构信息
Focus Program Translational Neuroscience, Rhine Main Neuroscience Network, Johannes Gutenberg University Medical Centre Mainz, Department of Neurology, Langenbeckstrasse 1, D-55131 Mainz, Germany.
出版信息
Nat Rev Neurol. 2013 Feb;9(2):72-3. doi: 10.1038/nrneurol.2012.277. Epub 2013 Jan 22.
PMID:23338282
Abstract
2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.
摘要
2012 年见证了多发性硬化症的重要发展，包括新型口服治疗药物的 III 期临床试验的成功，以及钾通道 KIR4.1 作为自身免疫靶标的鉴定。此外，肺部被强调为免疫细胞编程的重要部位，TNF 受体变体的相关性也得到了阐明。
Zotero 插件